Short Communication Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/neurobiology.3.011
Silibinin and neurological diseases
Neda Masoumi Qajari1, Abbas Khonakdar-Tarsi2,*
- 1M.Sc student of Genetic Biology, Islamic Azad University of Tonekabon, Tonekabon, Iran
- 2Department of Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Corresponding Author
Abbas Khonakdar-Tarsi, khonakdarab@gmail.com
Received Date: January 18, 2021
Accepted Date: February 16, 2021
Qajari NM, Khonakdar-Tarsi A. Silibinin and neurological diseases. J Neurobiol Physiol 2021; 3(1):8-9.
Copyright: © 2021 Qajari NM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Etrasimod: A promising therapeutic candidate against Multiple Sclerosis
Multiple sclerosis (MS) is central nervous system (CNS) based disease. It is a chronic inflammatory demyelinating disease [1]. The main causes for MS are genetic and environmental factors. It is a disease of young people (median age of onset is around 28 years) but is lifetime and is often disabling; 50% of patients need a cane to walk 15 years after disease onset; and Worldwide more than 2.5 Million persons are affected.
Fronting the twin challenges: Alzheimer’s and Parkinson’s disease
Alzheimer's and Parkinson's diseases are two of the most prominent and complex progressive neurological disorders that have a profound global impact [1,2]. These diseases affect millions of individuals worldwide, causing significant morbidity and placing a substantial burden on healthcare systems and society [3,6]. Despite considerable advancements in understanding these disorders over the years, developing effective treatments remains a complex and multifaceted challenge [7,8].
Involvement of TGFβ signaling pathway in oxidative stress and diabetic retinopathy
Diabetic Retinopathy (DR) is a leading cause of blindness in the U.S. However, not much is known of underlying molecular mechanism and how oxidative stress contributes to its development. In the present study, we investigated the involvement of TGFβ signaling pathway on the effect of oxidative stress on VEGF secretion and viability of retinal cells. VEGF is the hallmark that exacerbates DR progression in prolonged diabetes. Some major concerns that have arisen are the underlying effects of antioxidants in elevating VEGF secretion in diabetes.
Role of Ginseng in therapeutic management of Alzheimer’s Disease
While much of research progress has been achieved in last century on Alzheimer’s Disease (AD), the conclusive therapy for the same is still unachieved. Several lines of therapeutic regimes have been introduced, which basically act on slowing down the disease progression.
Parkinson’s disease: cell therapy vs. gene therapy
Parkinson’s disease (PD) is the second most common neurodegenerative disease, manifesting as a characteristic movement disorder with a number of additional non-motor features. The pathological hallmark of PD is the presence of intra-neuronal aggregates of a-synuclein (Lewy bodies). The movement disorder of PD occurs largely due to loss of dopaminergic neurons of the substantia nigra, resulting in striatal dopamine depletion.